Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation

Leukemia and Lymphoma

Volumn 47, Issue 8, 2006, Pages 1488-1494

  Puig, Noemí ^a   De La Rubia, Javier ^a   Remigia, María J ^a   Jarque, Isidro ^a   Martín, Guillermo ^a   Cupelli, Luca ^a   Sanz, Guillermo F ^a   Lorenzo, Ignacio ^a   Sanz, Jaime ^a   Martínez, Jesús A ^a   Jiménez, Carmen ^a   Sanz, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Autologous transplantation; Conditioning regimen; Lymphoid malignancies; Transplant related mortality

Indexed keywords

ACICLOVIR; ALTEPLASE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DEFIBROTIDE; DIURETIC AGENT; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; MELPHALAN; MESNA; PENTOXIFYLLINE;

ADULT; AGE; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; BACTERIAL INFECTION; BONE MARROW APLASIA; CANCER MORTALITY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PROTOCOL; DISEASE ACTIVITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HODGKIN DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUCOSA INFLAMMATION; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; SIDE EFFECT; SINUSOIDAL OBSTRUCTION SYNDROME; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFECTION; LEUKEMIA, LYMPHOCYTIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, LYMPHOID; LYMPHOMA, SMALL-CELL; MALE; MELPHALAN; MIDDLE AGED; MORBIDITY; MORTALITY; PODOPHYLLOTOXIN; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 33748526486     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500527769     Document Type: Article

References (46)

1. Linch, D and Winfield, D and Goldstone, A and Moir, D and Hancock, B and McMillan, A and (1993) Dose intensification in autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial Lancet, 341, pp. 1051-1054.
2. Schmitz, N and Pfistner, B and Sextro, M and Sieber, M and Carella, A and Haenel, M and (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial Lancet, 359, pp. 2065-2071.
3. Philip, T and Guglielmi, C and Hagenbeek, A and Somers, R and Van der Lelle, H and Bron, D and (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med, 333, pp. 1540-1545.
4. Verdonck, L and Van Putten, W and Hagenbeek, A and Schouten, H and Sonneyeld, P and van Imhoff, O and (1995) Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma N Engl J Med, 332, pp. 1045-1051.
5. Stockerl-Goldstein, K and Horning, S and Negrin, R and Chao, N and Hu, W and Long, O and (1996) Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma Biol Blood Marrow Transplants, 2, pp. 76-85.
6. Vose, J and Anderson, J and Kessinger, A and Bierman, P and Loccla, P and Reed, E and (1993) High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma J Clin Oncol, 11, pp. 1846-1851.
7. Rapoport, A and Row, J and Kouides, P and Puerst, R and Abboud, C and Liesveld, J and (1993) One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome J Clin Oncol, 11, pp. 2351-2361.
8. Nademanee, A and Molina, A and O'Donnell, M and Dagis, A and Snyder, D and Parker, P and (1997) Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk, intermediate and high-grade lymphoma: International Index High and High-Intermediate Risk Group Blood, 90, pp. 3844-3852.
9. Bierman, P and Armitage, J. (1993) Role of autotransplantation in Hodgkin's disease Hematol Oncol Clin North Am, 7, pp. 591-611.
10. Goldstone, A and McMillan, A. (1993) The place of high dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease Ann Oncol, 4, pp. 21-27.
11. Chopra, R and McMillan, A and Linch, D and Yuklea, S and Taghipour, G and Pearce, R and (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients Blood, 81, pp. 1137-1145.
12. Wang, E and Chen, Y and Corringham, S and Bashey, A and Holman, P and Ball, E and (2004) High-dose CEB vs. BEAM with autologous stem cell transplant in lymphoma Bone Marrow Transplant, 34, pp. 581-587.
13. Arranz, R and Tomas, J and Gil-Fernández, J and Martinez-Chamorro, C and Granados, E and Alegre, A and (1998) Autologous stem cell transplantation for poor prognostic Hodgkin's disease: comparative results with two CBV regimens and importance of disease status at transplant Bone Marrow Transplant, 21, pp. 779-786.
14. Carella, A and Congiu, A and Gaozza, E and Mazza, P and Ricci, P and Visani, G and (1986) High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian Study Group report J Clin Oncol, 6, pp. 1411-1416.
15. Reece, D and Connors, J and Spinelli, J and Barnett, M and Fairey, R and Klingeman, H and (1994) Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy Blood, 83, pp. 1193-1199.
16. Wheeler, C and Eickhoff, C and Elias, A and Ibrahim, J and Ayash, L and McCauley, M and (1997) High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes Biol Blood Marrow Transplants, 3, pp. 98-106.
17. Sureda, A and Arranz, R and Iriondo, A and Carreras, E and Lahuerta, J and Garcia-Conde, J and (2001) Autologous stem-cell transplantation for Hodgkin's Disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group J Clin Oncol, 19, pp. 1395-1404.
18. Horning, S and Chao, N and Negrin, R and Hoppe, R and Long, G and Hu, W and (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices Blood, 89, pp. 801-813.
19. Patti, C and Majolino, I and Scime, R and Indovina, A and Vasta, S and Liberti, G and (1993) High-dose cyclophosphamide, etoposide and carmustine (CVB) with autologous stem cell rescue in malignant lymphomas Eur J Haematol, 51, pp. 18-24.
20. Strauss, D and Gaynor, J and Myers, J and Merke, D and Caravelli, J and Chapman, D and (1990) Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non cross-resistant chemo-therapy and intermediate-dose radiation therapy J Clin Oncol, 8, pp. 1173-1186.
21. Coiffier, B and Lepage, E. (1989) Prognosis of aggressive lymphoma: A study of five prognostic models with patients included in the LNH 84 regimen Blood, 74, pp. 558-564.
22. Villela, L and Sureda, A and Canals, C and Sanz, M, Jr and Martino, R and Valcárcel, D and (2003) Low transplant-related mortality in older patients with hematological malignancies undergoing autologous stem cell transplantation Haematologica, 88, pp. 300-305.
23. McDonald, G and Sharma, P and Matthews, D and Shulman, H and Thomas, E. (1984) Veno-occlusive disease of the liver after marrow transplantation: diagnosis, incidence, and predisposing factors Hepatology, 4, pp. 116-122.
24. Jones, R and Lee, K and Beschorner, W and Vogel, V and Grochow, L and Braine, H and (1987) Veno-occlusive disease of the liver following bone marrow transplantation Transplantation, 44, pp. 778-783.
25. Chap, L and Shpiner, R and Levine, M and Norton, L and Lill, M and Glaspy, J and (1997) Pulmonary toxicity of high-dose chemotherapy for breast cancer: A non-invasive approach to diagnosis and treatment Bone Marrow Transplant, 20, pp. 1063-1067.
26. Bearman, S and Appelbaum, F and Back, A and (1989) Regimen-related toxicity and early post-transplant survival in patients undergoing marrow transplantation for lymphoma J Clin Oncol, 7, pp. 1288-1294.
27. Bianco, J and Appelbaum, F and Nemuanitis, J and Almgren, J and Andrews, F and Kettner, P and (1991) Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation Blood, 78, pp. 1205-1211.
28. Kaplan, E and Meier, P. (1958) Nonparametric estimation from incomplete observations J Am Stat Assoc, 53, pp. 457-481.
29. Gray, R. (1988) A class of K-sample test for comparing the cumulative incidence of competing risk Ann Stat, 16, pp. 1141-1154.
30. Pepe, M and Mori, M. (1993) Kaplan-Meier, marginal or conditional probability curves in summarizing competing risk failure time data Stat Med, 12, pp. 737-751.
31. Reece, D and Barnett, M and Connors, J and Fairey, R and Fay, J and Greer, J and (1991) Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease J Clin Oncol, 9, pp. 1871-1879.
32. Reece, D and Connors, J and Spinelli, J and Barnett, M and Fairey, R and Klingemann, H and (1994) Intensive therapy with cyclophosphamide, carmustine, etoposide, cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy Blood, 83, pp. 1193-1199.
33. Reece, D and Barnett, M and Shepherd, J and Hogge, D and Klasa, R and Nantel, S and (1995) High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy Blood, 86, pp. 451-456.
34. Ayash, L and Hunt, M and Antman, K and Nadler, L and Wheeler, C and Takvorian, T and (1990) Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas J Clin Oncol, 8, pp. 1699-1706.
35. Locasciulli, A and Bacigalupo, A and Alberti, A and van Lint, M and Uderzo, C and Marmont, A and (1989) Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation Transplantation, 48, pp. 68-72.
36. Morgan, M and Dodds, A and Atkinson, K and Szer, J and Downs, K and Biggs, J and (1991) The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation Br J Haematol, 77, pp. 529-534.
37. McDonald, G and Hinds, M and Fisher, L and Schoch, H and Wolford, J and Banajl, M and (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients Ann Intern Med, 118, pp. 255-267.
38. Carreras, E and Bertz, H and Arcese, W and Verhant, J and Tomas, J and Hagglund, H and (1998) European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation Blood, 92, pp. 3599-3604.
39. Wadhwa, P and Fu, P and Koc, O and Cooper, B and Fox, R and Creger, R and (2005) High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: An effective regimen with low morbidity and mortality Biol Blood Marrow Transplants, 11, pp. 13-22.
40. Todd, N and Peters, W and Ost, A and Roggli, V and Piantadosi, C and (1993) Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation Am Rev Respir Dis, 147, pp. 1264-1270.
41. Cherniack, R and Abrams, J and Kalica, J. (1994) Pulmonary disease associated with breast cancer therapy Am J Resp Crit Care Med, 150, pp. 1169-1173.
42. Stuart, M and Chao, N and Horning, S and Wong, R and Negrin, R and Johnston, L and (2001) Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen foll-owed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease Biol Blood Marrow Transplants, 7, pp. 552-560.
43. Ager, S and Mahendra, P and Richards, E and Bass, G and Baglin, T and Marcus, R and (1996) High-dose carmustine, etoposide and melphalan (BEM) with autologous stem cell transplantation: A dose-toxicity study Bone Marrow Transplant, 17, pp. 335-340.
44. Wheeler, C and Antin, J and Churchill, W and Come, S and Smith, B and Bubley, G and (1990) Cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non Hodgkin's lymphoma: A dose-finding study J Clin Oncol, 8, pp. 648-656.
45. Cao, T and Negrin, R and Stockerl-Goldstein, K and Johnston, L and Shizuru, J and Taylor, T and (2000) Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation Biol Blood Marrow Transplants, 6, pp. 387-394.
46. Gutierrez-Delgado, F and Holmberg, L and Hooper, H and Petersdorf, S and Press, O and Maziarz, R and (2003) Autologous stem cell transplantation for Hodgkin's disease: Busulfan, melphalan and thiotepa compared to a radiation-based regimen Bone Marrow Transplant, 32, pp. 279-285.